Female Contraception Clinical Trial
Official title:
A Randomized, Cross-over, Clinical Trial to Assess the Prevention of Ovulation Achieved by Single Intra-vaginal Administration of 0.75 mg Levonorgestrel (LNG) Gel (Levogel) as Compared to 1.5 mg Oral LNG
It has been proposed that levonorgestrel (LNG) in a vaginal gel could be used as an 'on demand' contraceptive when used before coitus. Levonorgestrel was selected as it is a component of many approved oral contraceptive pills and also it is the active agent in Plan B, an FDA-approved regimen for emergency contraception (EC). In previous studies it was demonstrated that an LNG vaginal gel was absorbed and was effective in preventing follicular rupture. The overall proportion of cycles with lack of follicular rupture within 5 days of LNG administration or with ovulatory dysfunction (follicle rupture preceded by an inadequate LH surge) was 96% for LNG gel and 39% in the inert gel cycles (control group).
A dose of 0.75mg of LNG in a vaginal gel was shown to prevent ovulation in a higher
percentage than what has been observed with oral LNG at the approved doses for EC of 1.5mg.
Results from a study with a1.5 mg LNG oral dose or a single 0 ,75mg dose demonstrated that
the proportion of cycles without follicle rupture or ovulatory dysfunction within 5 days was
86% and 79% respectively (Croxatto et al, 2004) , whereas lack of follicular rupture or the
presencr of ovulatory dsyfunction was 96% with administration of a LNG gel formulation. In
the group of women with follicle size ≥18mm the gel induced 50% ovulation suppression while
oral LNG in previous studies blocked only 16% of ovulation in the same follicle size group .
These encouraging results could be explained by higher bioavailability of LNG when
administered vaginally. This comparison was made using historical data from another study;
therefore this study will compare vaginal administration of LNG to oral in a direct
cross-over comparative study.
LNG is known to affect the cervical mucus by making it hostile to sperm penetration and its
effect may appear after only a few hours following oral administration (Kesseru, 1984;
Brache, unpublished observations). Application of LNG gel in the vagina close to the cervical
os may exert a direct effect on the cervical mucus. The potential local action of LNG on the
cervical mucus may be another important mechanism by which protection is conferred to women
who do not experience ovulation suppression.
An "on demand" precoital contraceptive is an attractive alternative to the post-coital
emergency contraception currently available, especially due to the higher efficacy of this
route of administration on ovulation suppression as compared with oral tablets of LNG. Should
the present study confirm the superiority of vaginal administration of half the dose of the
oral dose of LNG approved for emergency contraception, further development of that
formulation and method would be warranted.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06394999 -
Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
|
Phase 3 | |
Completed |
NCT00653016 -
An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method
|
Phase 4 | |
Completed |
NCT00511784 -
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
|
N/A | |
Completed |
NCT00236769 -
A Study of Efficacy and Safety With the Transdermal Contraceptive System.
|
Phase 3 | |
Active, not recruiting |
NCT03124160 -
Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
|
Phase 3 | |
Completed |
NCT00709189 -
Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.
|
Phase 1 | |
Completed |
NCT00258063 -
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
|
Phase 1 | |
Completed |
NCT00775086 -
Bioequivalence Study of Patches With Different Equilibration Profiles
|
Phase 1 | |
Recruiting |
NCT04143659 -
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
|
Phase 1 | |
Completed |
NCT00697307 -
Bioequivalence Study of Patches With Different Release Profiles
|
N/A | |
Completed |
NCT00261482 -
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
|
Phase 4 | |
Completed |
NCT00236795 -
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
|
Phase 3 | |
Completed |
NCT01833793 -
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice
|
N/A | |
Recruiting |
NCT02257671 -
Oral Contraceptives and Economic Behaviour
|
N/A | |
Recruiting |
NCT03432416 -
Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring
|
Phase 2 | |
Completed |
NCT01178125 -
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
|
Phase 3 | |
Completed |
NCT00254865 -
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT00258076 -
A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)
|
Phase 1 | |
Completed |
NCT00331071 -
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
|
N/A | |
Completed |
NCT00377988 -
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
|
N/A |